
    
      This clinical trial is designed to include two parts:

      Part 1: Assessment of feasibility and safety of administering YM155 in combination with
      docetaxel and prednisone in subjects with hormone refractory prostate cancer (HRPC) [
      ENROLLMENT COMPLETED ]

      Part 2: Assessment of feasibility and safety of administering YM155 in combination with
      docetaxel in subjects with solid tumors (except HRPC).

      This registration has been updated to reflect the design requirements of PART 2.
    
  